September 16, 2019
  • September 16, 2019
Breaking News
  • Home
  • Markets
  • Market Snap Shot: Atossa Genetics Inc. (NASDAQ:ATOS), Seelos Therapeutics, Inc. (NASDAQ:SEEL), Zogenix, Inc. (NASDAQ:ZGNX), Evoke Pharma, Inc. (NASDAQ:EVOK)

Market Snap Shot: Atossa Genetics Inc. (NASDAQ:ATOS), Seelos Therapeutics, Inc. (NASDAQ:SEEL), Zogenix, Inc. (NASDAQ:ZGNX), Evoke Pharma, Inc. (NASDAQ:EVOK)

By on June 28, 2019 0

Atossa Genetics Inc. (NASDAQ:ATOS) reported that its preliminary Phase 2 Study achieved its primary endpoint for the topical Endoxifen that rapidly reduces breast density.

Atossa Genetics Inc. (NASDAQ:ATOS), a Healthcare sector firm, traded 14.95 Million shares in last trading session with closing price of $2.58 per share. Stock value has moved between $0.8 – 7.37 in last one year. Analyst’s mean target price for Atossa Genetics Inc. (NASDAQ:ATOS) is $9.00. ATOS EPS growth this year is 49.80%.

Seelos Therapeutics, Inc. (NASDAQ:SEEL) acquired the license of gene therapy program to address Parkinson’s disease from Duke University. The gene therapy program targets the regulation of the SNCA gene. Seelos plans to study this approach, named SLS-004, initially in Parkinson’s disease.

On last trading day, Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares closed at $2.32 per share. SEEL market capitalization is 47.84 with beta of 0.79. Analyst’s mean target price for Seelos Therapeutics, Inc. (NASDAQ:SEEL) is $6.00 whereas analysts mean recommendation is 2.00. Its weekly performance is 5.45% while year to date (YTD) performance is -59.72%.

Zogenix, Inc. (NASDAQ:ZGNX) reported an FDA deal to proceed with the resubmission of its FINTEPLA new drug application.

In last session Zogenix, Inc. (NASDAQ:ZGNX) traded 4.77 Million shares and was closed at $47.65. Analyst’s mean target price for ZGNX is $57.09 while analysts mean recommendation is 1.70. Company is -24.06% away from its 52 week high and is moving 42.54% ahead of its 52 week low. ZGNX return on assets is -22.00%. Zogenix, Inc. (NASDAQ:ZGNX) quarterly performance is -12.63%.

Evoke Pharma, Inc. (NASDAQ:EVOK) requested a Type A FDA meeting to plan for the resubmission of Gimoti NDA. Evoke Pharma, Inc. (NASDAQ:EVOK), a Healthcare sector firm, traded 3.75 Million shares on last trading day with closing price of $0.57 per share. Stock value has moved between $0.5 – 3.35 in last one year. Analyst’s mean target price for Evoke Pharma, Inc. (NASDAQ:EVOK) is $8.00 while analysts mean recommendation is 2.50. EVOK EPS growth this year is 44.50%.

  Markets
Leave a comment